Market revenue in 2023 | USD 4,028.7 million |
Market revenue in 2030 | USD 5,664.5 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.07% in 2023. Horizon Databook has segmented the Europe inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest market share in 2022. The presence of organizations, such as European Crohn’s and Colitis Organization, Crohn’s & Colitis UK, and The European Chronic Disease Alliance, is leading to an increase in awareness about inflammatory bowel disease in the region.
Moreover, the growing demand for more effective medications and the increasing prevalence of IBD in this region are likely to be some of the key market drivers. According to European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), approximately 3.4 million Europeans are affected by any of the types of IBD, and the prevalence of the disease is rising.
The presence of well-established healthcare infrastructure in this region is anticipated to contribute to the market growth in the coming years. According to the EFCCA, the direct healthcare cost of IBD is around USD 6.62 billion annually.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe inflammatory bowel disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account